The Establishment and Maintenance of a Comprehensive Thoracic Tumor Data Registry and Bioreceptor 
Aims: The purpose of this database is to allow researchers to review and compare medical information including medical history, symptoms, medical test results, treatments and complications that people with thoracic tumor may have. Another purpose of this study is to collect leftover tissue obtained during thoracic surgery or diagnostic tests. Research testing of this tissue may help to determine the changes which lead to the development and/or spread of cancer. This information may help to develop new kinds of diagnostic
Diagnosis: Thoracic Cancer
Principal Investigator: John Howington, MD
IRB Approval Number: EH98-136
Sponsor: NorthShore University HealthSystem
Contact: Interested patients should contact research coordinator Ujala Bokary at 847.570.1783
Open to Enrollment: Yes

UC12-1726: A Randomized Phase II Study of IV Topotecan versus CRLX101 in the Second-Line Treatment of Recurrent Small Cell Lung Cancer
Aims: The purpose of this study is to find out what effecrts, good and/or bad, the experimental drug CRLX101 has on you and your small cell lung cancer. CRLX101 is an experimental drug that is a new formulation of an anti-cancer drug called camptothecin (CPT). Like topotecan, CPT blocks the topoisomerase I enzyme. It is hoped that this new formulation of CPT will have fewer side effects than prior formulations of CPT and will be more effective in blocking the topoisomerase I enzyme. CRLX101 has not been approved by the Food and Drug Administration for use in small cell lung cancer. 
Diagnosis: Small Cell Lung Cancer
Principal Investigator: Thomas Hensing, MD
IRB Approval Number: EH13-163
Sponsor: Cancer and Leukemia Group B (CALGB)
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes

E2511: A Phase I and Randomized Phase II Double Blind Clinical Trial of Displatin and Etoposide in Combination with Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Aims: The purpospurpose of this study is two parts. In the first part of the study (phase I) we wanted to first ascertain that it is safe to allow patients to take an additional investigational pill (veliparib) along with the standard chemotherapy (cisplatin and etoposide) for the treatment of their lung cancer. Cisplatin and etoposide were chosen for this trial because the benefits and risks are well known, and because together they are one of the most effective therapies against small cell lung cancer or large cell neuroendocrine NSCC. In the second part of this study (phase II) we want to compare the effects, good and/or bad, of veliparib or a placebo (inactive pill) when combined with the standard commonly-used drugs (cisplatin and etoposide) on you and your type of lung cancer to find out which is better. If you participate in the second part of this study, you will get either veliparib or the placebo pill. You will not get both. However, you will get the standard chemotherapy drugs irrespective of which type of pill you are getting. You are being asked to take part in the phase II portion of the study.
Diagnosis: Small Cell Lung Cancer
Principal Investigator: Thomas Hensing, MD
IRB Approval Number: EH13-193
Sponsor: Eastern Cooperative Oncology Group (ECOG)
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes

UC12-2158: NCI 9267: A Phase 2 Study of ARQ 197 in Patients with Previously Treated Malignant Mesothelioma
Aims: The purpose of this study is to determine whether ARQ 197 can shrink tumors in mesothelioma patients. This research is being done because more effective treatments need to be developed for this disease if standard treatments stop working.
Diagnosis: Malignant Mesothelioma
Principal Investigator: Nicholas Campbell, MD
Sponsor: University of Chicago
Contact: For more information, interested participants may contact research nurse, Michele Britto, RN at 847.570.2109
Open to Enrollment:
Yes

ABI-007-NSCL-005: Safety and efficacy of nab ® -paclitaxel (Abraxane ®) in combination with carboplatin with carboplatin as first line treatment in elderly subjects with advanced non-small cell lung cancer (NSCLC): A Phase IV, randomized, open-label, multicenter study
Aims: This study will compare two schedules of this combination in patietns who are at least 70 years old. The purpose of this study is to find out which nab-paclitaxel/caboplatin schedule is better tolerated and to compare efficacy between the two schedules.
Diagnosis: Non-Small Cell Lung Cancer
Principal Investigator: Thomas Hensing, MD
IRB Approval Number: EH14-256
Sponsor: Celgene Corporation
Contact: Interested patients should contact research nurse Michele Britto at 847.570.2109
Open to Enrollment: Yes

S1400: Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer
Aims: The purpose of this study screening step is to perform genetic tests on your tumor sample for certain features that investigational targeted agents used in this study are specifically designed to work against. Then the purpose is to assign you to a treatment sub-study that is chosen based on the results (genes and proteins called "biomarkers") of this genetic testing on your tumor sample. This study related "research test" will be done in a special lab. The system of assigning a treatment sub-study based on genetic testing of cancer is investigational; in squamous cell lung cancer patients, we don’t know whether testing can identify patients who will or will not benefit from treatment. The purpose of the treatment part of this study is to compare the effects, good and bad, of these investigational agents to the usual approach to treating your type of cancer. It may be possible that you will not be able to participate in the treatment part of this study. This could happen if it is unsafe for you to receive the investigational treatment. You may also choose to not participate in the treatment portion of the study. Before you decide to get treatment on the study, you will be given information about the study treatment and you will be asked if you wish to continue on this research study.
Diagnosis: Squamous Cell Lung Cancer
Principal Investigator: Thomas Hensing, MD
IRB Approval Number: EH14-415
Sponsor: Southwest Oncology Group
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes

M11-089: Randomized, Double-Blind, Multicenter, Phase 3 Trial Comparing Veliparib Plus Carboplatin and Paclitaxel versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
Aims: This study is being done to research the effects of an investigational drug called veliparib in subjects with squamous NSCLC.Veliparib (also sometimes known as ABT-888) is a PARP inhibitor (blocker) that is not approved for use in advanced or metastatic NSCLC by the United States Food and Drug Administration (FDA) or by regulatory authorities in other countries outside of the US. PARP is a naturally occurring protein made by your body that may help cancer cells overcome injury or damage caused by radiation and certain types of anti-cancer drugs, making these treatments less effective. Veliparib inhibits (blocks) the activity of PARP. This blocking activity may prevent the cancer cell from repairing itself and resume growing.
Diagnosis: Squamous Non-Small Cell Lung Cancer
Principal Investigator: Nicholas Campbell, M.D.
IRB Approval Number: EH14-287
Sponsor: AbbVie Inc.
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes

CALGB 140503: A Phase III Randomized Trial of Lobectomy versus Sublobar Resection for Small (≤ 2 cm) Peripheral Non-Small Cell Lung Cancer
Aims: The purpose of this study is to investigate two types of surgery for patients with small (≤ 2 cm) Peripheral Non-Small Cell Lung Cancers. The study will evaluate the effectiveness of the surgery in keeping the tumor from recurring as well as the effect of the different surgeries on lung function. The study will also examine the use of CT and PET scans in detecting cancer.
The Study duration: Surgery is scheduled and the patient will be in the hospital postoperatively as determined by the physician.
Follow-up: After surgery the patient will be followed for a minimum of 5 years: post operatively as determined by the surgeon, then every 6 months for 2 years, then annually.
Diagnosis: Non-Small Cell Lung Cancer ≤ 2 cm located in the periphery of the lung.
Principal Investigator: John Howington, MD
IRB Approval Number: EH12-430
Sponsor: Cancer and Leukemia Group B (CALGB)
Contact: For more information, interested participants may contact the Surgical Research Office at 847.570.1783 or ubokhary@northshore.org
Open to Enrollment: Yes

× Alternate Text